Intercept Pharmaceuticals

FDA rejects Intercept’s pitch for NASH as CEO fires back at the agency’s ‘evolving’ guidelines
FDA rejects Intercept’s pitch for NASH as CEO fires back at the agency’s ‘evolving’ guidelines
Endpoints
Intercept Pharmaceuticals
NASH
FDA
obeticholic acid
Flag link:
Gilead/Galapagos, Intercept and Corbus trials could be hit by coronavirus spread: analyst
Gilead/Galapagos, Intercept and Corbus trials could be hit by coronavirus spread: analyst
Fierce Biotech
clinical trials
Gilead Sciences
Galapagos
Corbus Pharmaceuticals
Intercept Pharmaceuticals
coronaviruses
COVID-19
Flag link:
JP Morgan Preview: Small, Medium and Large, with a Lot of M&A Speculation
JP Morgan Preview: Small, Medium and Large, with a Lot of M&A Speculation
BioSpace
JPMHC 2020
M&A
Exelixis
Intercept Pharmaceuticals
Avidity Biosciences
Theravance
Moderna Therapeutics
Kodiak Sciences
Flag link:
Intercept's NASH decision delayed by FDA, but don't panic: analysts
Intercept's NASH decision delayed by FDA, but don't panic: analysts
Fierce Pharma
Intercept Pharmaceuticals
NASH
obeticholic acid
FDA
Flag link:
2 NASH drugmakers have wildly different Mondays
2 NASH drugmakers have wildly different Mondays
Biopharma Dive
Intercept Pharmaceuticals
CymaBay Therapeutics
FDA
NASH
seladelpar
obeticholic acid
Flag link:
These 6 biotech stocks are promising takeover targets
These 6 biotech stocks are promising takeover targets
Marketwatch
M&A
Sarepta Therapeutics
Amarin
Intercept Pharmaceuticals
Immunomedics
Alder Biopharmaceuticals
Biogen
Flag link:
Intercept Tries to Outrun Pharma in Race for the Next Blockbuster
Intercept Tries to Outrun Pharma in Race for the Next Blockbuster
Bloomberg
liver disease
NASH
Intercept Pharmaceuticals
OCA
obeticholic acid
Flag link:
2 Biotechs With Big Dates in April
2 Biotechs With Big Dates in April
Motley Fool
Alnylam
EASL
Intercept Pharmaceuticals
Onpattro
givosiran
NASH
Ocaliva
Flag link:
Intercept Pharma is One Step Closer to Filing for Approval of First NASH Treatment
Intercept Pharma is One Step Closer to Filing for Approval of First NASH Treatment
BioSpace
NASH
Intercept Pharmaceuticals
obeticholic acid
OCA
clinical trials
Flag link:
Is the Smoldering NASH Market Ready to Burst Into Flames?
Is the Smoldering NASH Market Ready to Burst Into Flames?
BioSpace
NASH
Allergan
Regeneron
Alnylam
AstraZeneca
Merck
Takeda
Gilead Sciences
Bristol-Myers Squibb
Intercept Pharmaceuticals
Flag link:
Intercept Pharmaceuticals Announces Pricing of Upsized $250 Million Public Offering and Concurrent Private Placement of Common Stock
Intercept Pharmaceuticals Announces Pricing of Upsized $250 Million Public Offering and Concurrent Private Placement of Common Stock
CP Wire
Intercept Pharmaceuticals
Flag link:
3 Mid-Cap Biotech Stocks That May Be Red-Hot Takeover Candidates
3 Mid-Cap Biotech Stocks That May Be Red-Hot Takeover Candidates
Motley Fool
biotech
M&A
Exelixis
Portola Pharmaceuticals
Intercept Pharmaceuticals
Flag link:
Could These 2 Small Biotechs Beat Allergan and Gilead Sciences?
Could These 2 Small Biotechs Beat Allergan and Gilead Sciences?
Motley Fool
biotech
Allergan
Gilead Sciences
Genfit
Intercept Pharmaceuticals
NASH
Flag link:
Seven $1 billion-plus drugs seen reaching market in 2016
Seven $1 billion-plus drugs seen reaching market in 2016
Yahoo/Reuters
Intercept Pharmaceuticals
Gilead Sciences
Roche
AbbVie
Merck
obeticholic acid
emtricitabine
Flag link:
2015's Worst Clinical Failures
2015's Worst Clinical Failures
Motley Fool
clinical trials
liver disease
cancer pain
Eli Lilly
Intercept Pharmaceuticals
GW Pharma
Flag link:
Intercept's much-hyped NASH drug misses the mark in Phase II
Intercept's much-hyped NASH drug misses the mark in Phase II
Fierce Biotech
Intercept Pharmaceuticals
NASH
Sumitomo Dainippon
Japan
OCA
Flag link:
5 Biotech Stocks On Deck With The FDA
5 Biotech Stocks On Deck With The FDA
Yahoo/Benzinga
FDA
Alnylam
Patisiran
Esperion Therapeutics
ETC-1002
Intercept Pharmaceuticals
obeticholic acid
Sarepta Therapeutics
eteplirsen
Tekmira
TKM-PLK1
Flag link:
4 Biotech and Pharma Stocks Projected to Rise 50% to 100%
4 Biotech and Pharma Stocks Projected to Rise 50% to 100%
24/7 Wall St
Flex Pharma
Intercept Pharmaceuticals
Intra-Cellular Therapies
SteadyMed
Flag link:
Why Intercept Might Be A Better Bet Than Biogen Right Now
Why Intercept Might Be A Better Bet Than Biogen Right Now
Yahoo/Benzinga
Intercept Pharmaceuticals
Biogen Idec
Flag link:
3 Leading Biotech Stocks Releasing Potential Catalyst Data This Week
3 Leading Biotech Stocks Releasing Potential Catalyst Data This Week
24/7 Wall St
Amgen
evolocumab
Biogen Idec
BIIB037
OCA
obeticholic acid
Intercept Pharmaceuticals
Flag link:

Pages